BUZZ-Bind Therapeutics Inc: Credit Suisse halves price target

jueves 4 de diciembre de 2014 12:55 GYT

** Drug developer's shares down 7 pct at $6.28

** Credit Suisse halves price target to $10, saying it does not expect data from mid-stage trial of prostate cancer drug to be conclusive to support a late-stage trial

** Company's lead drug met the main goal in a mid-stage trial in lung cancer patients.

** Credit Suisse expects data from mid-stage study of the same drug in prostate cancer patients towards year-end or early 2015

** Median price target on stock $20

** Up to Wednesday's close, stock had lost 55 pct this year